2023-09-28-世界卫生组织-2._A_H1N1_pdm09_-_Cell_culture-derived_-_Southern_Hemisphere_2024_2页_225kb

报告摘要

The World Health Organization (WHO) recommends cell culture-derived candidate vaccine viruses (ccCVVs) for developing influenza vaccines aimed at the 2024 southern hemisphere flu season, specifically for Influenza A(H1N1)pdm09.
WHO Collaborating Centers (CCs) part of the Global Influenza Surveillance and Response System (GISRS) isolate viruses using certified cell lines, such as MDCK 33016 (developed for human vaccine use), and conduct antigenic and genetic analyses on these viruses.
Antigenic similarity is confirmed through two-way hemagglutination inhibition (HI) or virus neutralization (VN) tests against prototype viruses matching WHO recommendations. No additional testing, like adventitious agents analysis, is performed.
National or regional control authorities review and approve vaccine manufacture, composition, and formulation for use in individual countries.
Key strains include A/Georgia/12/2022 and A/West Virginia/30/2022, with viruses like A/Wisconsin/67/2022 reassortants; for recombinant antigens, protein sequences must closely match specific reference strains.
Contact details and order information are provided, noting that manufacturers should consult local authorities before using ccCVVs and referencing WHO resources for more details.